Economic Observation Network Lily's stock price has risen due to the influx of funds into the defense sector, and has recently received rating and target price upgrades from multiple institutions.

Recent Stock Trends
On October 15th, Eli Lilly continued to rise 2% in pre-market trading, and rose 3.6% against the trend the previous day. The main logic is that after the US September CPI exceeded expectations, concerns about the Federal Reserve raising interest rates intensified, and funds withdrew from AI technology stocks (the Philadelphia Semiconductor Index fell 4.3%) and shifted to defense sectors such as healthcare. As a pharmaceutical leader with both growth attributes, Eli Lilly benefited significantly 。

Institutional Perspective
Analysts are intensively raising their expectations. Morgan Stanley's target price has been raised from 1419 to $1430, maintaining a buy position; Bank of America reiterates its buy, with a target price of $1341; RBC expects annual revenue to reach $89.8 billion, maintaining a lead over the market, with a target price of $1500 。

The above content is based on publicly available information and does not constitute investment advice.